Month: May 2020

Amsterdam, The Netherlands, May 13, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces three abstracts supporting the potential of the Company’s K-NK cell therapy program to treat relapsed/refractory acute myeloid leukemia (R/R ML) have been accepted at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting taking place May 29 – 31, 2020.The ASCO abstracts are now available at https://meetings.asco.org/am/virtual-format. Details of the presentations are as follows:·  Abstract #3025 has been accepted as a poster and presents clinical data of a subset of R/R AML patients with CNS disease treated with FC21-NK cells in a phase I/II study (NCT02809092).Abstract DetailsTitle: CD56bright/CD16bright NK-cell adoptive immunotherapy...

Amsterdam, 13 mei 2020 – Kiadis Pharma N.V. (‘Kiadis Pharma’ of de ‘Onderneming’) (Euronext Amsterdam en Brussel: KDS), gaat drie presentatie houden op de (dit jaar virtuele) bijeenkomst van de  American Society of Clinical Oncology (ASCO), van 29 mei tot 31 mei 2 2020. De drie presentaties zijn gericht op het potentieel van het KNK-celtherapieprogramma voor de behandeling van terugkerende acute myeloïde leukemie (R/R ML).De volledige ASCO presentaties  zijn beschikbaar op www.asco.org. Hier volgen nadere gegevens van de presentaties:·  Abstract 3025 is geaccepteerd als posterpresentatie en toont de klinische gegevens van een subset van R/R AML-patiënten met CNS-ziekte, die behandeld zijn met FC21-NK cellen in een fase I/II-studie (NCT02809092).Details van de presentatieTitel: ‘CD56bright/CD16bright NK-cell adoptive immunotherapy in patients...

BURLINGTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference. The fireside chat is scheduled to begin at 10:55 a.m. ET on Tuesday, May 19, 2020.To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.About Flexion TherapeuticsFlexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company’s core values are focus, ingenuity,...

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29-31, 2020.“We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “In addition, the oral presentation will feature compelling overall survival data from our RUN-HN Phase 2 trial...

OTTAWA, May 13, 2020 (GLOBE NEWSWIRE) — HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced that it received notification from the New York Stock Exchange (the “NYSE”) on April 7, 2020 that the Company was no longer in compliance with the NYSE’s US$1.00 share price continued listing standard (the “Price Listing Standard”) as a result of the average closing price of its common shares on the NYSE falling below US$1.00 for a consecutive 30 trading-day period. The issuance of the notification was not discretionary and is sent automatically when a listed company’s share price falls below the Price Listing Standard.Under the NYSE’s rules, the Company can regain compliance with the Price Listing Standard and avoid delisting if, within six months from the date of the NYSE notification, its common shares have...

OTTAWA, 13 mai 2020 (GLOBE NEWSWIRE) — HEXO Corp (« HEXO », ou la « Société ») a annoncé aujourd’hui que le 7 avril 2020 la Société a reçu un avis écrit de la Bourse de New York (le « NYSE ») indiquant que la Société ne satisfaisait pas actuellement à la norme de maintien de la cotation en bourse du NYSE à 1 dollar US (la « norme de cotation ») en raison de la chute du cours de clôture moyen de ses actions ordinaires au NYSE en dessous de 1 dollar US au bout de 30 jours de négociation consécutifs. L’émission de cet avis n’était pas discrétionnaire et se fait automatiquement lorsque le prix de l’action d’une société cotée tombe en dessous de la norme de cotation.En vertu des règles du NYSE, la Société peut se conformer de nouveau à la norme de cotation des prix et éviter d’être radiée de la cote...

WESTFORD, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) announced today that its Board of Directors has authorized the repurchase of up to $20 million of its equity securities effective May 13, 2020 through May 13, 2021. Repurchases may be made in public or private transactions, including under Securities Exchange Act Rule 10b-5-1 trading plans. The timing and amount of any repurchases will be at the discretion of Company management and will be based on market conditions and other considerations, including limitations contained in our credit agreement entered into on March 1, 2017, as amended. The Company has not repurchased any shares of its common stock under the existing $20 million authorization that will expire on May 15, 2020.About KadantKadant Inc. is a global supplier of high-value, critical components and...

Maintains strong balance sheet with EUR 18.5 million (USD 20.3 million) in cash as of March 31, 2020Signs exclusive worldwide distribution agreement with Exact Imaging to combine their innovative micro-ultrasound technology with Focal One to offer an end-to-end focal therapy solution for the diagnosis and management of prostate cancerAnnounces strategic refocusing of future development programs towards high intensity focused ultrasound (HIFU) and related growth opportunitiesCompany to host a conference call tomorrow, May 14 at 8:30 am EDTLYON, France, May 13, 2020 — EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the first quarter of 2020 and provided an update on strategic and operational developments. Marc Oczachowski, EDAP’s Chief Executive...

TORONTO, May 13, 2020 (GLOBE NEWSWIRE) — Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the “Corporation” or “Capstone”) today reports and filed its results for the first quarter ended March 31, 2020. The Corporation’s first quarter 2020 Management’s Discussion and Analysis (“MD&A”) and unaudited interim consolidated financial statements are available at www.capstoneinfrastructure.com and on SEDAR at www.sedar.com. Capstone’s MD&A details the “Results of Operations” and provides a “Financial Position Review” for the quarter ended March 31, 2020.Dividend DeclarationsThe board of directors today declared a quarterly dividend on the Corporation’s Cumulative Five-Year Rate Reset Preferred Shares, Series A (the “Preferred Shares”) of $0.2044 per Preferred...